Late-Breaking Clinical Trial Results Announced at The VEINS 2026
The VIVA Foundation presented late-breaking clinical trial results at The VEINS 2026 conference. Key findings include 88.1% ulcer healing rate with Cyanoacrylate Closure (CAC) for C6 disease, 100% technical success for the VEnice device in treating venous incompetence, and favorable 30-day results for the Abre Venous Stent System. The RAPID-PE study showed promising interim results for on-the-table mechanically channeled thrombolysis in acute intermediate-risk pulmonary embolism.
How this was made
The 30-second read
Why it matters
First‑time disclosure of efficacy and safety metrics for Medtronic‑related devices, providing new data points for analysts and investors.
Market read
Introduces fresh clinical evidence that could influence valuation of Medtronic and peers in the vascular‑intervention space.
What to watch
Potential reimbursement challenges and competition from alternative ablation technologies.
Background
The VIVA Foundation announced late‑breaking clinical trial data at the VEINS 2026 conference, covering cyanoacrylate closure, percutaneous vein ligation, and the Abre venous stent system.
Ticker impact
Medtronic (MDT) disclosed first‑report clinical trial outcomes for its VenaSeal cyanoacrylate closure system and Abre venous stent, showing high ulcer‑healing rates and low complication rates.
likely upward pressure as the market prices in improved product efficacy and potential sales growth.
The results are first‑time disclosures, show strong efficacy and safety, and involve a large, US‑listed medical‑device company.
Market effects
May lift sentiment for the broader vascular‑device and interventional cardiology sectors.
U.S. and European markets could see modest gains in med‑tech stocks.
Limited to healthcare investors; no broad macro impact.
Counterpoint
Investors may question long‑term adoption if larger comparative studies are not pursued.
Key entities
- CompanyMedtronic
US‑listed medical‑device maker (ticker MDT) responsible for VenaSeal and Abre stent.
